IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity
- Conditions
- Upper and/or Lower Limb Focal Spasticity
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 123
- Registration Number
- NCT04604379
- Locations
- 🇬🇧
York Hospital, York, United Kingdom
🇬🇧Kings College Hospital, London, United Kingdom
🇬🇧Colman Hospital, Norwich, United Kingdom
Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.
- Conditions
- Prostate Cancer
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 817
- Registration Number
- NCT04593420
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
- Conditions
- Primary Biliary Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 161
- Registration Number
- NCT04526665
- Locations
- 🇺🇸
Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States
🇿🇦Tiervlei Trial Centre, Cape Town, Western Cape, South Africa
Retrospective Real-Life Study From One Brazilian Reference Center Assessing Long-Term Experience In The Treatment Of Adult Spasticity With AbobotulinumtoxinA
- Conditions
- Spasticity
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 200
- Registration Number
- NCT04446702
- Locations
- 🇧🇷
Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP), San Paolo, Brazil
A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.
- Conditions
- Spasticity Related to Any Cause Except Cerebral Palsy
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 114
- Registration Number
- NCT04396704
- Locations
- 🇬🇧
North Staffordshire Rehabilitation Centre. Midlands Partnership NHS Foundation Trust., Stafford, United Kingdom
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
- Conditions
- Locally Advanced or Metastatic Renal Cell Carcinoma
- Interventions
- Drug: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 247
- Registration Number
- NCT04353765
- Locations
- 🇺🇸
McKesson Life Sciences, The Woodlands, Texas, United States
Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A
- Conditions
- Spasticity
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT04340336
- Locations
- 🇮🇹
Ubaldo Del Carro, Milano, Italy
🇮🇹Marecello Esposito, Milano, Italy
🇮🇹Morena Giovannelli, Roma, Italy
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Advanced or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 150
- Registration Number
- NCT04106349
- Locations
- 🇧🇪
Chirec Delta, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇧🇪Virga Jessa Ziekenhuis, Hasselt, Belgium
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 770
- Registration Number
- NCT04083235
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States
Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
- Conditions
- Adult Lower Limb Spasticity
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 438
- Registration Number
- NCT04050527
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Riverhills Healthcare, Cincinnati, Ohio, United States
🇺🇸OrthoNeuro, Columbus, Ohio, United States